PhaseBio Pharmaceuticals Overview

PhaseBio Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for PHAS.

Quarterly SG&A Expenses

$4.58M

↑ 13.81% YoY

As of Jun 30, 2022

Annual SG&A Expenses (TTM)

$1.25M

↓ 91.07% YoY

Trailing 12 months ending Jun 30, 2022

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin